Tmt212
Clinical Trials Overview
1 trials found
About Tmt212
Tmt212 is an investigational medication currently being studied by Novartis Pharmaceuticals. It is being evaluated in clinical trials, including one for colorectal cancer (CRC). The trials are in early phases (Phase 1), meaning they primarily focus on determining the safety and appropriate dosage of the drug, as well as looking for early signs of effectiveness. Tmt212 is often studied in combination with other experimental or approved therapies. The specific role of Tmt212 in treating CRC and its effectiveness are still under investigation.
Category
Other Medications
Mechanism
The specific way Tmt212 works (its mechanism of action) is being investigated in clinical trials. It is being studied in combination with other agents like PDR001, CJM112, EGF816, and canakinumab (Ilaris®) or trametinib (Mekinist®). The goal is to understand how Tmt212 interacts with these other drugs and affects the body, particularly in relation to cancer cells.
1
Total Trials
0
Recruiting
0
Active
1
Completed
283
Total Enrollment
9
Countries
NCT02900664
Phase 1
Completed
283 patients
The purpose of this study was to combine the PDR001 checkpoint inhibitor with each of four agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerability, pharmaco...
United States, Belgium, Canada, France, Israel, Italy, Singapore, Spain, Taiwan